Home

duplikat rijedak glup re dual pci trial ppt Pomol mosta žrtva Lutati

Prasugrel-based de-escalation of dual antiplatelet therapy after  percutaneous coronary intervention in patients with acute coronary syndrome  (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority  randomised trial - The Lancet
Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial - The Lancet

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial  Fibrillation | NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM

Direct-acting Anticoagulants in Chronic Coronary Syndromes | ECR Journal
Direct-acting Anticoagulants in Chronic Coronary Syndromes | ECR Journal

Temporal trends in prevalence and antithrombotic treatment among Asians  with atrial fibrillation undergoing percutaneous coronary intervention: A  nationwide Korean population-based study | PLOS ONE
Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study | PLOS ONE

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL  PCI Trial | JACC: Cardiovascular Interventions
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial  Fibrillation: Design, Rationale, and Status - tctmd.com
The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status - tctmd.com

Objectives, The Site, Finance, and Role of The Ethics Committee, Sponsor  and Research Organization
Objectives, The Site, Finance, and Role of The Ethics Committee, Sponsor and Research Organization

Slides: Anticoagulation 2017: The key lessons and implications from RE-CIRCUIT  / RE-DUAL PCI - PACE-CME
Slides: Anticoagulation 2017: The key lessons and implications from RE-CIRCUIT / RE-DUAL PCI - PACE-CME

Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL  PCI Trial | JACC: Cardiovascular Interventions
Evaluation of Dual Versus Triple Therapy by Landmark Analysis in the RE-DUAL PCI Trial | JACC: Cardiovascular Interventions

Atrial Fibrillation and PCI - ppt download
Atrial Fibrillation and PCI - ppt download

Atrial Fibrillation and PCI - ppt download
Atrial Fibrillation and PCI - ppt download

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial  Fibrillation | NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM

RE-DUAL PCI™ vs PIONEER AF-PCI™
RE-DUAL PCI™ vs PIONEER AF-PCI™

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial  Fibrillation | NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM

RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous  coronary intervention in patients with atrial fibril
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril

Dual Antithrombotic Therapy in AF Patients Undergoing PCI - Dr. ten B…
Dual Antithrombotic Therapy in AF Patients Undergoing PCI - Dr. ten B…

on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt  download
on behalf of the RE-DUAL PCI Steering Committee and Investigators - ppt download

Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute  Coronary Syndromes or Percutaneous Intervention | Journal of the American  College of Cardiology
Antithrombotic Therapy in Patients With Atrial Fibrillation After Acute Coronary Syndromes or Percutaneous Intervention | Journal of the American College of Cardiology

Atrial Fibrillation and PCI - ppt download
Atrial Fibrillation and PCI - ppt download

Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial  Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect
Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation: The RE-DUAL PCI Trial Subanalysis - ScienceDirect

Dual Antithrombotic Therapy in AF Patients Undergoing PCI - Dr. ten B…
Dual Antithrombotic Therapy in AF Patients Undergoing PCI - Dr. ten B…

Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com
Subgroup Analysis from the RE-DUAL PCI Trial | tctmd.com

Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial  Fibrillation | NEJM
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation | NEJM

RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous  coronary intervention in patients with atrial fibril
RE-DUAL PCI: dual antithrombotic therapy with dabigatran after percutaneous coronary intervention in patients with atrial fibril

Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen  after successful coronary stenting in patients with atrial fibrillation  (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial - The Lancet

AF and PCI in Practice. - ppt download
AF and PCI in Practice. - ppt download